These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 33162769)

  • 41. The Important Role of the Endocannabinoid System and the Endocannabinoidome in Gut Health.
    Meletis C
    Altern Ther Health Med; 2019 Jun; 25(S2):24-28. PubMed ID: 31202201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
    Wilkerson JL; Bilbrey JA; Felix JS; Makriyannis A; McMahon LR
    Pharmacol Biochem Behav; 2021 Jul; 206():173192. PubMed ID: 33932409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cannabinoids: Therapeutic Use in Clinical Practice.
    Pagano C; Navarra G; Coppola L; Avilia G; Bifulco M; Laezza C
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota.
    Suriano F; Manca C; Flamand N; Depommier C; Van Hul M; Delzenne NM; Silvestri C; Cani PD; Di Marzo V
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Jan; 1867(1):159056. PubMed ID: 34606993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation.
    Galve-Roperh I; Chiurchiù V; Díaz-Alonso J; Bari M; Guzmán M; Maccarrone M
    Prog Lipid Res; 2013 Oct; 52(4):633-50. PubMed ID: 24076098
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
    J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Lipidomics- and Transcriptomics-Based Analysis of the Intestine of Genetically Obese (
    Suriano F; Manca C; Flamand N; Van Hul M; Delzenne NM; Silvestri C; Cani PD; Di Marzo V
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Cannabinoids Effect on Bone Formation and Bone Healing.
    Raphael-Mizrahi B; Gabet Y
    Curr Osteoporos Rep; 2020 Oct; 18(5):433-438. PubMed ID: 32705630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
    Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD).
    Peng J; Fan M; An C; Ni F; Huang W; Luo J
    Basic Clin Pharmacol Toxicol; 2022 Apr; 130(4):439-456. PubMed ID: 35083862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders.
    Maia J; Fonseca BM; Teixeira N; Correia-da-Silva G
    Hum Reprod Update; 2020 Jun; 26(4):586-602. PubMed ID: 32347309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment.
    Asth L; Iglesias LP; De Oliveira AC; Moraes MFD; Moreira FA
    Epilepsy Behav; 2021 Aug; 121(Pt B):106832. PubMed ID: 31839498
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets.
    Vitale RM; Iannotti FA; Amodeo P
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting the Endocannabinoid System in Psychiatric Illness.
    Katzman MA; Furtado M; Anand L
    J Clin Psychopharmacol; 2016 Dec; 36(6):691-703. PubMed ID: 27811555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract.
    Lian J; Casari I; Falasca M
    Pharmacol Res; 2022 Jan; 175():106025. PubMed ID: 34883211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
    Al-Ghezi ZZ; Busbee PB; Alghetaa H; Nagarkatti PS; Nagarkatti M
    Brain Behav Immun; 2019 Nov; 82():25-35. PubMed ID: 31356922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacology of cannabinoids in the treatment of epilepsy.
    Gaston TE; Friedman D
    Epilepsy Behav; 2017 May; 70(Pt B):313-318. PubMed ID: 28087250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential Utility of Cannabidiol in Stress-Related Disorders.
    Lookfong NA; Raup-Konsavage WM; Silberman Y
    Cannabis Cannabinoid Res; 2023 Apr; 8(2):230-240. PubMed ID: 36409719
    [No Abstract]   [Full Text] [Related]  

  • 59. Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review.
    de Camargo RW; de Novais Júnior LR; da Silva LM; Meneguzzo V; Daros GC; da Silva MG; de Bitencourt RM
    Pharmacol Biochem Behav; 2022 Nov; 221():173492. PubMed ID: 36379443
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations.
    Aziz AI; Nguyen LC; Oumeslakht L; Bensussan A; Ben Mkaddem S
    Cannabis Cannabinoid Res; 2023 Apr; 8(2):254-269. PubMed ID: 36413346
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.